Dermapharm Holding SE (ETR:DMP)
Market Cap | 1.90B |
Revenue (ttm) | 1.20B |
Net Income (ttm) | 103.57M |
Shares Out | 53.84M |
EPS (ttm) | 1.92 |
PE Ratio | 18.30 |
Forward PE | 14.44 |
Dividend | 0.90 (2.56%) |
Ex-Dividend Date | Jun 27, 2025 |
Volume | 204 |
Average Volume | 25,343 |
Open | 35.30 |
Previous Close | 35.20 |
Day's Range | 35.20 - 35.30 |
52-Week Range | 30.15 - 42.50 |
Beta | 1.31 |
RSI | 35.54 |
Earnings Date | May 15, 2025 |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as product... [Read more]
Financial Performance
In 2024, Dermapharm Holding SE's revenue was 1.20 billion, an increase of 3.89% compared to the previous year's 1.15 billion. Earnings were 113.79 million, an increase of 82.44%.
Financial StatementsNews

Dermapharm Hits Q1 Targets, Reaffirms 2025 Outlook
Dermapharm Holding SE's Q1 2025 results align with expectations, driven by strong growth in key segments, despite some challenges, and affirming their full-year guidance. Jetzt den vollständigen Artik...

EQS-PVR: Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Dermapharm Holding SE Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wid...

EQS-DD: Dermapharm Holding SE: Susanne Gertrud Pia Lanz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 08.04.2025 / 16:43 CET/CEST The issuer is solely responsi...

Dermapharm's 2024: Revenue Soars, Surpassing EBITDA Expectations
Dermapharm's financial results for 2024 reflect a dynamic year of growth and strategic adjustments, setting a promising stage for the future. Jetzt den vollständigen Artikel lesen

EQS-News: Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance
EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Annual Report Successful financial year 2024: Dermapharm increases revenue and exceeds EBITDA guidance 28.03.2025 / 07:30 CET/CEST The iss...

EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 18.03.2025 / 13:12 CET/CEST The issuer is solely responsi...

Dermapharm Surpasses EBITDA Forecast with Revenue Boost
Dermapharm Holding SE's financial prowess shines with a 4% revenue boost, driven by 'Branded pharmaceuticals,' and a 10.2% EBITDA surge, setting the stage for promising growth in 2025. Jetzt den volls...

EQS-News: Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA
EQS-News: Dermapharm Holding SE / Key word(s): Annual Results/Preliminary Results Dermapharm Holding SE increases revenue as projected and exceeds guidance for adjusted consolidated EBITDA 14.03.2025 ...

EQS-DD: Dermapharm Holding SE: Wilhelm Beier, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 30.12.2024 / 12:38 CET/CEST The issuer is solely responsi...

EQS-DD: Dermapharm Holding SE: Dr. Hans-Georg Feldmeier, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 11.11.2024 / 16:30 CET/CEST The issuer is solely responsi...

EQS-DD: Dermapharm Holding SE: Christof Dreibholz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.11.2024 / 15:12 CET/CEST The issuer is solely responsi...

Dermapharm Holding SE: High-Margin Pharma Boosts Global Organic Growth
Dermapharm Holding SE showcases robust organic growth in its branded pharmaceuticals segment, offsetting a revenue dip from the cessation of pandemic-related vaccine production. Unadjusted EBITDA surg...

EQS-News: Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies
EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Half Year Report Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at Germa...

Dermapharm Holding: Thriving on High-Margin Organic Growth in Pharma Business
Despite a slight dip in overall revenue and earnings, strong performance in branded pharmaceuticals has helped Dermapharm navigate the post-pandemic landscape. The company remains optimistic about its...

EQS-News: Sustained organic growth in high-margin existing branded pharmaceutical business
EQS-News: Dermapharm Holding SE / Key word(s): Half Year Results/Preliminary Results Sustained organic growth in high-margin existing branded pharmaceutical business 14.08.2024 / 07:30 CET/CEST The is...